Biogen Inc. has announced the initiation of a Phase 3 study, named PROMINENT, to assess the efficacy and safety of felzartamab in the treatment of primary membranous nephropathy $(PMN)$. This global study will compare felzartamab, an investigational anti-CD38 monoclonal antibody, with tacrolimus in adults with PMN, a rare immune-mediated kidney disease currently lacking approved therapies. The study aims to address the unmet medical need for this condition, which affects approximately 36,000 patients in the U.S. alone. This marks the third Phase 3 trial of felzartamab initiated by Biogen this year, following studies for late antibody-mediated rejection in adult kidney transplant recipients and IgA nephropathy. The results of the PROMINENT study have not yet been presented.
免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。